Interleukin-15 signaling
Winthrop KL. Erratum: The emerging safety profile of JAK inhibitors in rheumatic disease. Nature Reviews Rheumatology. 2017 Mar 31;13(5):320. doi: 10.1038/nrrheum.2017.51.; Mishra A, Sullivan L, Caligiuri MA. Molecular pathways: interleukin-15 signaling in health and in cancer. Clin Cancer Res. 2014 Apr 15;20(8):2044–50. PMID: 24737791; PMCID: PMC3989546.; Wu Z, Xue HH, Bernard J, Zeng R, Issakov D, Bollenbacher-Reilley J, Belyakov IM, Oh S, Berzofsky JA, Leonard WJ. The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation. Blood. 2008 Dec 01;112(12):4411–9. PMID: 18796634; PMCID: PMC2597117.; Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity. 2002 Nov;17(5):537–47. doi: 10.1016/s1074-7613(02)00429-6. PMID: 12433361.; Gadina M, Sudarshan C, Visconti R, Zhou Y, Gu H, Neel BG, O'Shea JJ. The Docking Molecule Gab2 Is Induced by Lymphocyte Activation and Is Involved in Signaling by Interleukin-2 and Interleukin-15 but Not Other Common ? Chain-using Cytokines. Journal of Biological Chemistry. 2000 Sep;275(35):26959–66. doi: 10.1016/s0021-9258(19)61466-3.; Johnston JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, Shibuya K, Ortaldo JR, Gupta S, Chen YQ, Giri JD. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc. Natl. Acad. Sci. U.S.A. 1995 Sep 12;92(19):8705–9. doi: 10.1073/pnas.92.19.8705.